<DOC>
	<DOCNO>NCT01720524</DOCNO>
	<brief_summary>This study evaluate whether IV sildenafil reduce time inhale nitric oxide treatment reduce failure rate available treatment persistent pulmonary hypertension newborn .</brief_summary>
	<brief_title>A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Neonates persistent pulmonary hypertension newborn Age &lt; =96 hour &gt; =34 week gestational age Oxygenation Index &gt; 15 &lt; 60 Concurrent treatment inhale nitric oxide &gt; =50 % oxygen Prior immediate need extracorporeal membrane oxygenation cardiopulmonary resuscitation Expected duration mechanical ventilation &lt; 48 hour Profound hypoxemia Lifethreatening lethal congenital anomaly</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Days</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>persistent pulmonary hypertension</keyword>
	<keyword>newborn</keyword>
	<keyword>neonate</keyword>
	<keyword>iv sildenafil</keyword>
	<keyword>hypoxic respiratory failure risk persistent pulmonary hypertension newborn</keyword>
</DOC>